Synthesis, in vivo rhesus monkey biodistribution and in vitro evaluation of a 11C-labelled potent aromatase inhibitor: [N-methyl-11C]vorozole.

[1]  H. Onoe,et al.  Methodological aspects for in vitro characterization of receptor binding using 11C-labeled receptor ligands: a detailed study with the benzodiazepine receptor antagonist [11C]Ro 15-1788. , 1997, Nuclear medicine and biology.

[2]  M. Dowsett,et al.  In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  B. Långstrom,et al.  Mao-a enzyme binding in bladder-cancer characterized with [C-11] harmine in frozen-section autoradiography. , 1995, Oncology reports.

[4]  M. Dowsett,et al.  ARIMIDEX™: A new oral, once-a-day aromatase inhibitor , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  A. Brodie,et al.  Aromatase inhibitors in the treatment of breast cancer , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  T. Watanabe,et al.  Receptor autoradiography with 11C and [3H]-labelled ligands visualized by imaging plates. , 1992, Neuroreport.

[7]  A. Raeymaekers,et al.  Comparative effects of the aromatase inhibitor R76713 and of its enantiomers R83839 and R83842 on steroid biosynthesis in vitro and in vivo , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  M. Dowsett,et al.  Aromatase inhibitors and hormone-dependent cancers , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  P. Cole,et al.  Mechanism and inhibition of cytochrome P-450 aromatase. , 1990, Journal of medicinal chemistry.

[10]  R. Santen.  Clinical use of aromatase inhibitors: current data and future perspectives. , 1990, Journal of enzyme inhibition.

[11]  G. Antoni,et al.  Synthesis of L- and D-[methyl-11C]methionine. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  M. Dowsett,et al.  A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients. , 1985, British Journal of Cancer.

[13]  M. Dowsett,et al.  4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCER , 1984, The Lancet.

[14]  A. Green.  Tomoxifen versus aminoglutethimide in advanced breast carcinoma , 1982 .

[15]  R. Santen,et al.  Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. , 1982, Annals of internal medicine.

[16]  A. Harris,et al.  Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. , 1981, British medical journal.

[17]  H. Brodie,et al.  Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta. , 1973, Endocrinology.